An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG).
No Thumbnail Available
Embargo End Date
ICR Authors
Authors
Kasper, B
Baumgarten, C
Garcia, J
Bonvalot, S
Haas, R
Haller, F
Hohenberger, P
Penel, N
Messiou, C
van der Graaf, WT
Gronchi, A
Desmoid Working Group,
Baumgarten, C
Garcia, J
Bonvalot, S
Haas, R
Haller, F
Hohenberger, P
Penel, N
Messiou, C
van der Graaf, WT
Gronchi, A
Desmoid Working Group,
Document Type
Journal Article
Date
2017-10-01
Date Accepted
2017-06-13
Abstract
Desmoid-type fibromatosis is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Currently, there is no established or evidence-based treatment approach available for this disease. Therefore, in 2015 the European Desmoid Working Group published a position paper giving recommendations on the treatment of this intriguing disease. Here, we present an update of this consensus approach based on professionals' AND patients' expertise following a round table meeting bringing together sarcoma experts from the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group with patients and patient advocates from Sarcoma PAtients EuroNet. In this paper, we focus on new findings regarding the prognostic value of mutational analysis in desmoid-type fibromatosis patients and new systemic treatment options.
Citation
Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 28 (10), pp. 2399 - 2408
Source Title
Publisher
OXFORD UNIV PRESS
ISSN
0923-7534
eISSN
1569-8041
Collections
Research Team
Clinical and Translational Sarcoma
Sarcoma Clinical Trials
Sarcoma Clinical Trials